Brief: FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer
BRIEF-FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer Nov 13 (Reuters) - FDA:
FDA APPROVES DURVALUMAB WITH ENFORTUMAB VEDOTIN-EJFV FOR MUSCLE INVASIVE BLADDER CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)